A Phase 2 interventional study of Enzalutamide in Advanced, Androgen Receptor Positive Triple Negative Breast Cancer, sponsored by Pfizer. Completed at 132 sites in 7 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-13.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing enzalutamide in Breast Neoplasms — 1 open to participants now, 3 under way, none of them phase 3. enzalutamide · Breast Neoplasms.
Among the 13 studies testing enzalutamide in Breast Neoplasms, this one is the 3rd largest by enrollment, is one of 2 that started in 2013, is one of 9 in phase 2, and was the 2nd registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.
Browse Breast Neoplasms studies →1 of the 13 studies testing enzalutamide in Breast Neoplasms is open now, in 1 country. Recruiting first, the newest first:
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
enzalutamide: first FDA approval 2012 (XTANDI), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 2 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 118 is above the median of 72 across 10,903 interventional studies indexed under Breast Neoplasms.
Median enrollment 61 across the 13 interventional studies. Of the 9 that completed or were terminated, 6 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 13 have an industry lead sponsor. The 7 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
182 studies in Breast Neoplasms by Pfizer: 6 open now, 26 under way, 7 of them phase 3. Of 145 finished, 94 (65%) have results posted.
Among the 182 studies in Breast Neoplasms by Pfizer, this one is the 47th largest by enrollment of the 121 interventional ones that give a count, is one of 10 that started in 2013, is one of 43 in phase 2, and was the 72nd registered.
Pfizer’s Breast Neoplasms studies by the year they started, since 1998.
2 of the studies testing enzalutamide in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02750358Memorial Sloan Kettering Cancer CenterFeasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer | 2027-05 |
| NCT06099769Memorial Sloan Kettering Cancer CenterA Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer | 2027-10 |
Add all 2 to your calendar (.ics) → With an account.
Among the 13 studies testing enzalutamide in Breast Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 182 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if enzalutamide is safe and effective in the treatment of patients with advanced breast cancer that express the androgen receptor but do not express the estrogen or progesterone receptor and are not Her2 amplified.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
160 mg administered as four 40 mg soft gelatin capsules orally once daily
Drug: Enzalutamide
160 mg administered as four soft gelatin capsules orally once daily
Also known as: Xtandi®, MDV3100
Percentage of Participants With Clinical Benefit at Week 16: Evaluable Population
Percentage of participants with a clinical benefit at Week 16 defined as percentage of participants with a best response of complete response (CR), partial response(PR), stable disease(SD) for \>=16 weeks on radiologic imaging based on Investigator assessment using Response Evaluation Criteria in Solid Tumors version 1.1(RECIST 1.1). An estimate of the percentage and its exact 2-sided 85% confidence interval(CI) were calculated using the Blaker method. As per RECIST 1.1, CR defined as disappearance of all target, non-target lesions and normalization of tumor marker level and all lymph nodes decreased to non-pathological in size \<10mm short axis. PR: At least 30% decrease in sum of longest diameter (LD) of target lesions taking as reference baseline sum of LD, without progression of non-target lesions, no appearance of new lesions. SD: Neither sufficient reduction to qualify as PR nor sufficient increase to qualify as PD, using the smallest sum diameters during the study as a reference.
Time frame: Week 16
Percentage of Participants With Clinical Benefit at Week 16: Intent-to-Treat (ITT) Population
Percentage of participants with a clinical benefit at Week 16 defined as percentage of participants with a best response of CR, PR, or SD for \>= 16 weeks on radiologic imaging based on Investigator assessment using RECIST 1.1. An estimate of the percentage and its exact 2-sided 85% CI were calculated using the Blaker method. As per RECIST 1.1, CR defined as disappearance of all target, non-target lesions and normalization of tumor marker level and all lymph nodes decreased to non-pathological in size \<10 mm short axis. PR: At least 30% decrease in sum of LD of target lesions taking as reference baseline sum of LD, without progression of non-target lesions, no appearance of new lesions. SD: Neither sufficient reduction to qualify as PR nor sufficient increase to qualify as PD, using the smallest sum diameters during the study as a reference.
Time frame: Week 16
Percentage of Participants With Clinical Benefit at Week 24: Evaluable Population
Percentage of participants with a clinical benefit at Week 24 defined as percentage of participants with a best response of CR, PR, or SD for \>= 24 weeks on radiologic imaging based on investigator assessment using RECIST 1.1. An estimate of the percentage and its exact 2-sided 85% CI were calculated using the Blaker method. As per RECIST 1.1, CR defined as disappearance of all target, non-target lesions and normalization of tumor marker level and all lymph nodes decreased to non-pathological in size \<10 mm short axis. PR: At least 30% decrease in sum of LD of target lesions taking as reference baseline sum of LD, without progression of non-target lesions, no appearance of new lesions. SD: Neither sufficient reduction to qualify as PR nor sufficient increase to qualify as PD, using the smallest sum diameters during the study as a reference.
Time frame: Week 24
Percentage of Participants With Clinical Benefit at Week 24: ITT Population
Percentage of participants with a clinical benefit at Week 24 defined as percentage of participants with a best response of CR, PR, or SD for \>= 24 weeks on radiologic imaging based on investigator assessment using RECIST 1.1. An estimate of the percentage and its exact 2-sided 85% CI were calculated using the Blaker method. As per RECIST 1.1, CR defined as disappearance of all target, non-target lesions and normalization of tumor marker level and all lymph nodes decreased to non-pathological in size \<10 mm short axis. PR: At least 30% decrease in sum of LD of target lesions taking as reference baseline sum of LD, without progression of non-target lesions, no appearance of new lesions. SD: Neither sufficient reduction to qualify as PR nor sufficient increase to qualify as PD, using the smallest sum diameters during the study as a reference.
Time frame: Week 24
Percentage of Participants With Best Objective Response: Evaluable Population
Percentage of participants with best objective response defined as percentage of participants with a best response of CR and PR based on investigator assessment of target, non-target and new lesions using RECIST 1.1. As per RECIST 1.1, CR defined as disappearance of all target, non-target lesions and normalization of tumor marker level and all lymph nodes decreased to non-pathological in \<10 mm short axis. PR: At least 30% decrease in sum of LD of target lesions taking as reference baseline sum of LD, without progression of non-target lesions, no appearance of new lesions.
Time frame: From Baseline up to disease progression or death due to any cause (up to 87 Weeks)
Percentage of Participants With Best Objective Response: ITT Population
Percentage of participants with best objective response defined as percentage of participants with a best response of CR and PR based on investigator assessment of target, non-target and new lesions using RECIST 1.1. As per RECIST 1.1, CR defined as disappearance of all target, non-target lesions and normalization of tumor marker level and all lymph nodes decreased to non-pathological in \<10 mm short axis. PR: At least 30% decrease in sum of LD of target lesions taking as reference baseline sum of LD, without progression of non-target lesions, no appearance of new lesions.
Time frame: From Baseline up to disease progression or death due to any cause (up to 87 Weeks)
Progression-Free Survival (PFS): Evaluable Population
PFS was defined as the time (in weeks) from the date of first dose of study drug to the date of documented disease progression or death due to any cause whichever occurs first as determined by the investigator using RECIST 1.1. As per RECIST 1.1, progression was defined as: \>=20 percent increase in sum of LD of target lesions taking as a reference the smallest sum of the LD recorded since the treatment started, or the appearance of one or more new lesions and/or unequivocal progression of existing non target-lesions.
Time frame: From Baseline up to disease progression or death due to any cause (up to 87 Weeks)
Progression-Free Survival: ITT Population
PFS was defined as the time (in weeks) from the date of first dose of study drug to the date of documented disease progression or death due to any cause whichever occurs first as determined by the investigator using RECIST 1.1. As per RECIST 1.1, progression was defined as: \>=20 percent increase in sum of LD of target lesions taking as a reference the smallest sum of the LD recorded since the treatment started, or the appearance of one or more new lesions and/or unequivocal progression of existing non target-lesions.
Time frame: From Baseline up to disease progression or death due to any cause (up to 87 Weeks)
Time to Response: Evaluable Population
The time to response is defined as the time from the date of first dose of study drug to initial CR or PR. Participants without response of CR or PR before the data cutoff date were censored at the last tumor assessment date before the data cutoff. Kaplan-Meier method was used to summarize time to response.
Time frame: From first dose of study drug until first documentation of CR or PR or data censoring date, whichever occurred first (up to 87 Weeks)
Duration of Response: Evaluable Population
Duration of objective response is defined as the time from initial CR or PR to documented disease progression or death due to any cause, whichever occurs first. Participants without disease progression or death due to any cause before the data cutoff date were censored at the last tumor assessment date before the data cutoff.
Time frame: From first documentation of CR or PR until first documentation of tumor progression or death due to any cause or data censoring date, whichever occurred first (up to 87 Weeks)
Number of Participants With Postbaseline Laboratory Toxicities Grade 3 or 4
Laboratory parameters included hematology parameters \[low lymphocytes (10\^6/L), neutrophils (10\^6/L) and Leukocytes (10\^9/L)\] and chemistry parameters \[high phosphate (mmol/L), bilirubin, Alkaline phosphatase (U/L) and glucose (mmol/L)\]. Number of participants with postbaseline laboratory toxicity Grade 3 or 4 as per NCI-CTCAE (version 4.0) (Grade 3= Severe, Grade 4= Life-threatening) were reported.
Time frame: From start of study treatment on Day 1 up to 30 days after the last dose of study drug (up to maximum of 9.6 years)
Trough Plasma Concentration of Enzalutamide and Its Metabolite
M2 was the metabolite of enzalutamide. The lower limit of quantitation (LLQ) was 0.0200 micrograms per milliliter (mcg/mL) for enzalutamide and M2.
Time frame: Predose on Day 1 (Baseline), Week 9 and Week 17
Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment emergent are events that were absent before treatment or that worsened relative to pretreatment state between first dose of study drug and up to 30 days after last dose of study drug or the day prior to initiation of new anti-tumor treatment. AEs included both serious and non-serious AEs.
Time frame: Baseline up to 87 weeks
Number of Participants With Study Drug Discontinuation Due to Adverse Events
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Data reported here is for study drug discontinuation due to adverse events.
Time frame: Baseline up to 87 weeks
Number of Participants With Grade 3 or Higher Adverse Events
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Severity of the AEs was graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. As per the NCI CTCAE, version 4.0, Grade 3= severe, Grade 4= life-threatening and Grade 5= death. Only the participants with treatment-emergent AEs of Grade 3 (severe) or higher grade were reported in this outcome measure.
Time frame: Baseline up to 87 weeks
Number of Participants With Clinically Significant Change From Baseline in Vital Signs
Criteria: Systolic blood pressure (SBP):absolute SBP\<90 millimeters of mercury (mmHg) and decrease from baseline (DFB)\>30mmHg, absolute SBP\>180mmHg and increase from baseline (IFB)\>40 mmHg, final visit (FV) or 2 consecutive visits (CV) SBP\>=20 mmHg change from baseline (CFB), most extreme post-baseline SBP\>=140mmHg, most extreme post- baseline SBP\>=180mmHg, most extreme SBP\>=140mmHg and\>=20 mmHg CFB, most extreme SBP\>=180mmHg and\>=20mmHg CFB; diastolic blood pressure (DBP): absolute DBP\>105mmHg and IFB\>30mmHg, absolute DBP\<50mmHg and DFB\>20mmHg, final visit or 2 consecutive visits DBP\>=15mmHg CFB, most extreme post-baseline DBP\>=90mmHg, most extreme post-baseline DBP\>=105mmHg, most extreme DBP\>=90mmHg and\>=15mmHg CFB, most extreme DBP\>=105mmHg and\>=15mmHg CFB; heart rate\<50beats per minute (BPM) and DFB\>20BPM or heart rate\>120BPM and IFB\>30BPM. Only those categories, in which at least 1 participant had data were reported.
Time frame: From start of study treatment on Day 1 up to 30 days after the last dose of study drug (up to maximum of 9.6 years)
Number of Participants With Change From Baseline in Laboratory Parameters Grades by 2 or More Grades
Laboratory tests included hematology parameters \[low lymphocytes (10\^6/L), white blood cells (10\^9/L), neutrophils (10\^6/L), hemoglobin gram per Liter(g/L) and platelets (10\^9/L)\] and chemistry parameters \[mean albumin grams per Liter(g/L), calcium milli mole per Liter(mmol/L), Phosphate (mmol/L), alanine aminotransferase units per Liter(U/L), Aspartate aminotransferase (U/L), bilirubin micro mole per Liter, Alkaline phosphatase (U/L) and glucose (mmol/L)\]. Number of participants with change from baseline in laboratory parameters Grades by 2 or More Grades as per NCI-CTCAE (version 4.0) (Grade 2=Moderate, Grade 3= Severe, Grade 4= Life-threatening) were reported.
Time frame: From start of study treatment on Day 1 up to 30 days after the last dose of study drug (up to maximum of 9.6 years)
Total of 118 participants with advanced androgen receptor positive (AR+) and triple-negative breast cancer (TNBC) were enrolled at total of 34 study sites in North America and Europe to attain total of 78 evaluable participants.
| Milestone | Enzalutamide |
|---|---|
| Started | 118 |
| Completed | 0 |
| Not completed | 118 |
| Withdrew: Death | 1 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Adverse event | 6 |
| Withdrew: Disease progression | 104 |
| Withdrew: Other | 6 |
Percentage of participants with a clinical benefit at Week 16 defined as percentage of participants with a best response of complete response (CR), partial response(PR), stable disease(SD) for \>=16 weeks on radiologic imaging based on Investigator assessment using Response Evaluation Criteria in Solid Tumors version 1.1(RECIST 1.1). An estimate of the percentage and its exact 2-sided 85% confidence interval(CI) were calculated using the Blaker method. As per RECIST 1.1, CR defined as disappearance of all target, non-target lesions and normalization of tumor marker level and all lymph nodes decreased to non-pathological in size \<10mm short axis. PR: At least 30% decrease in sum of longest diameter (LD) of target lesions taking as reference baseline sum of LD, without progression of non-target lesions, no appearance of new lesions. SD: Neither sufficient reduction to qualify as PR nor sufficient increase to qualify as PD, using the smallest sum diameters during the study as a reference.
| Percentage of participants | Enzalutamide |
|---|---|
| Percentage of Participants With Clinical Benefit at Week 16: Evaluable Population | 33.3 (25.53 to 41.63) |
Percentage of participants with a clinical benefit at Week 16 defined as percentage of participants with a best response of CR, PR, or SD for \>= 16 weeks on radiologic imaging based on Investigator assessment using RECIST 1.1. An estimate of the percentage and its exact 2-sided 85% CI were calculated using the Blaker method. As per RECIST 1.1, CR defined as disappearance of all target, non-target lesions and normalization of tumor marker level and all lymph nodes decreased to non-pathological in size \<10 mm short axis. PR: At least 30% decrease in sum of LD of target lesions taking as reference baseline sum of LD, without progression of non-target lesions, no appearance of new lesions. SD: Neither sufficient reduction to qualify as PR nor sufficient increase to qualify as PD, using the smallest sum diameters during the study as a reference.
| Percentage of participants | Enzalutamide |
|---|---|
| Percentage of Participants With Clinical Benefit at Week 16: Intent-to-Treat (ITT) Population | 24.6 (18.98 to 30.88) |
Percentage of participants with a clinical benefit at Week 24 defined as percentage of participants with a best response of CR, PR, or SD for \>= 24 weeks on radiologic imaging based on investigator assessment using RECIST 1.1. An estimate of the percentage and its exact 2-sided 85% CI were calculated using the Blaker method. As per RECIST 1.1, CR defined as disappearance of all target, non-target lesions and normalization of tumor marker level and all lymph nodes decreased to non-pathological in size \<10 mm short axis. PR: At least 30% decrease in sum of LD of target lesions taking as reference baseline sum of LD, without progression of non-target lesions, no appearance of new lesions. SD: Neither sufficient reduction to qualify as PR nor sufficient increase to qualify as PD, using the smallest sum diameters during the study as a reference.
| Percentage of participants | Enzalutamide |
|---|---|
| Percentage of Participants With Clinical Benefit at Week 24: Evaluable Population | 28.2 (21.04 to 36.48) |
Percentage of participants with a clinical benefit at Week 24 defined as percentage of participants with a best response of CR, PR, or SD for \>= 24 weeks on radiologic imaging based on investigator assessment using RECIST 1.1. An estimate of the percentage and its exact 2-sided 85% CI were calculated using the Blaker method. As per RECIST 1.1, CR defined as disappearance of all target, non-target lesions and normalization of tumor marker level and all lymph nodes decreased to non-pathological in size \<10 mm short axis. PR: At least 30% decrease in sum of LD of target lesions taking as reference baseline sum of LD, without progression of non-target lesions, no appearance of new lesions. SD: Neither sufficient reduction to qualify as PR nor sufficient increase to qualify as PD, using the smallest sum diameters during the study as a reference.
| Percentage of participants | Enzalutamide |
|---|---|
| Percentage of Participants With Clinical Benefit at Week 24: ITT Population | 20.3 (15.16 to 26.21) |
Percentage of participants with best objective response defined as percentage of participants with a best response of CR and PR based on investigator assessment of target, non-target and new lesions using RECIST 1.1. As per RECIST 1.1, CR defined as disappearance of all target, non-target lesions and normalization of tumor marker level and all lymph nodes decreased to non-pathological in \<10 mm short axis. PR: At least 30% decrease in sum of LD of target lesions taking as reference baseline sum of LD, without progression of non-target lesions, no appearance of new lesions.
| Percentage of participants | Enzalutamide |
|---|---|
| Percentage of Participants With Best Objective Response: Evaluable Population | 8.5 (3.05 to 12.02) |
Percentage of participants with best objective response defined as percentage of participants with a best response of CR and PR based on investigator assessment of target, non-target and new lesions using RECIST 1.1. As per RECIST 1.1, CR defined as disappearance of all target, non-target lesions and normalization of tumor marker level and all lymph nodes decreased to non-pathological in \<10 mm short axis. PR: At least 30% decrease in sum of LD of target lesions taking as reference baseline sum of LD, without progression of non-target lesions, no appearance of new lesions.
| Percentage of participants | Enzalutamide |
|---|---|
| Percentage of Participants With Best Objective Response: ITT Population | 6.2 (2.80 to 8.95) |
PFS was defined as the time (in weeks) from the date of first dose of study drug to the date of documented disease progression or death due to any cause whichever occurs first as determined by the investigator using RECIST 1.1. As per RECIST 1.1, progression was defined as: \>=20 percent increase in sum of LD of target lesions taking as a reference the smallest sum of the LD recorded since the treatment started, or the appearance of one or more new lesions and/or unequivocal progression of existing non target-lesions.
| Weeks | Enzalutamide |
|---|---|
| Progression-Free Survival (PFS): Evaluable Population | 14.3 (8.3 to 16.1) |
PFS was defined as the time (in weeks) from the date of first dose of study drug to the date of documented disease progression or death due to any cause whichever occurs first as determined by the investigator using RECIST 1.1. As per RECIST 1.1, progression was defined as: \>=20 percent increase in sum of LD of target lesions taking as a reference the smallest sum of the LD recorded since the treatment started, or the appearance of one or more new lesions and/or unequivocal progression of existing non target-lesions.
| Weeks | Enzalutamide |
|---|---|
| Progression-Free Survival: ITT Population | 12.6 (8.1 to 15.1) |
M2 was the metabolite of enzalutamide. The lower limit of quantitation (LLQ) was 0.0200 micrograms per milliliter (mcg/mL) for enzalutamide and M2.
| mcg/mL | Enzalutamide |
|---|---|
| Enzalutamide: Day 1 | NA ± NA |
| M2: Day 1 | NA ± NA |
| Enzalutamide: Week 9 | 12.59 ± 33.46 |
| M2: Week 9 | 13.48 ± 35.64 |
| Enzalutamide: Week 17 | 12.79 ± 37.33 |
| M2: Week 17 | 13.88 ± 25.47 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment emergent are events that were absent before treatment or that worsened relative to pretreatment state between first dose of study drug and up to 30 days after last dose of study drug or the day prior to initiation of new anti-tumor treatment. AEs included both serious and non-serious AEs.
| Participants | Enzalutamide |
|---|---|
| Treatment emergent adverse events | 109 |
| Treatment emergent serious adverse events | 29 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Data reported here is for study drug discontinuation due to adverse events.
| Participants | Enzalutamide |
|---|---|
| Number of Participants With Study Drug Discontinuation Due to Adverse Events | 8 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Severity of the AEs was graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. As per the NCI CTCAE, version 4.0, Grade 3= severe, Grade 4= life-threatening and Grade 5= death. Only the participants with treatment-emergent AEs of Grade 3 (severe) or higher grade were reported in this outcome measure.
| Participants | Enzalutamide |
|---|---|
| Number of Participants With Grade 3 or Higher Adverse Events | 36 |
Criteria: Systolic blood pressure (SBP):absolute SBP\<90 millimeters of mercury (mmHg) and decrease from baseline (DFB)\>30mmHg, absolute SBP\>180mmHg and increase from baseline (IFB)\>40 mmHg, final visit (FV) or 2 consecutive visits (CV) SBP\>=20 mmHg change from baseline (CFB), most extreme post-baseline SBP\>=140mmHg, most extreme post- baseline SBP\>=180mmHg, most extreme SBP\>=140mmHg and\>=20 mmHg CFB, most extreme SBP\>=180mmHg and\>=20mmHg CFB; diastolic blood pressure (DBP): absolute DBP\>105mmHg and IFB\>30mmHg, absolute DBP\<50mmHg and DFB\>20mmHg, final visit or 2 consecutive visits DBP\>=15mmHg CFB, most extreme post-baseline DBP\>=90mmHg, most extreme post-baseline DBP\>=105mmHg, most extreme DBP\>=90mmHg and\>=15mmHg CFB, most extreme DBP\>=105mmHg and\>=15mmHg CFB; heart rate\<50beats per minute (BPM) and DFB\>20BPM or heart rate\>120BPM and IFB\>30BPM. Only those categories, in which at least 1 participant had data were reported.
| Participants | Enzalutamide |
|---|---|
| SBP:Most extreme SBP>=140 mmHg and>=20 mmHg CFB | 12 |
| SBP: absolute SBP <90 mmHg and DFB>30 mmHg | 1 |
| SBP: Most extreme post baseline SBP >=140 mmHg | 42 |
| SBP: Most extreme post baseline SBP >=180 mmHg | 1 |
| DBP:Most extreme DBP>=90 mmHg and>=15 mmHg CFB | 12 |
| DBP:Most extreme DBP>=105 mmHg and>=15 mmHg CFB | 2 |
| DBP: Most extreme post baseline result >=90 mmHg | 24 |
| DBP: Most extreme post baseline result >=105 mmHg | 4 |
Laboratory tests included hematology parameters \[low lymphocytes (10\^6/L), white blood cells (10\^9/L), neutrophils (10\^6/L), hemoglobin gram per Liter(g/L) and platelets (10\^9/L)\] and chemistry parameters \[mean albumin grams per Liter(g/L), calcium milli mole per Liter(mmol/L), Phosphate (mmol/L), alanine aminotransferase units per Liter(U/L), Aspartate aminotransferase (U/L), bilirubin micro mole per Liter, Alkaline phosphatase (U/L) and glucose (mmol/L)\]. Number of participants with change from baseline in laboratory parameters Grades by 2 or More Grades as per NCI-CTCAE (version 4.0) (Grade 2=Moderate, Grade 3= Severe, Grade 4= Life-threatening) were reported.
| Participants | Enzalutamide |
|---|---|
| Hematology: Hemoglobin | 1 |
| Hematology: Leukocytes | 4 |
| Hematology: Lymphocytes | 12 |
| Hematology: Neutrophils | 2 |
| Hematology: Platelets | 1 |
| Chemistry: Alanine aminotransferase | 1 |
| Chemistry: Albumin | 4 |
| Chemistry: Alkaline phosphatase | 5 |
| Chemistry: Bilirubin | 2 |
| Chemistry: Calcium | 2 |
| Chemistry: Glucose | 5 |
| Chemistry: Phosphate | 4 |
| Chemistry: Aspartate Aminotransferase | 1 |
The time to response is defined as the time from the date of first dose of study drug to initial CR or PR. Participants without response of CR or PR before the data cutoff date were censored at the last tumor assessment date before the data cutoff. Kaplan-Meier method was used to summarize time to response.
| Weeks | Enzalutamide |
|---|---|
| Time to Response: Evaluable Population | NA (NA to NA) |
Duration of objective response is defined as the time from initial CR or PR to documented disease progression or death due to any cause, whichever occurs first. Participants without disease progression or death due to any cause before the data cutoff date were censored at the last tumor assessment date before the data cutoff.
| Weeks | Enzalutamide |
|---|---|
| Duration of Response: Evaluable Population | NA (NA to NA) |
Laboratory parameters included hematology parameters \[low lymphocytes (10\^6/L), neutrophils (10\^6/L) and Leukocytes (10\^9/L)\] and chemistry parameters \[high phosphate (mmol/L), bilirubin, Alkaline phosphatase (U/L) and glucose (mmol/L)\]. Number of participants with postbaseline laboratory toxicity Grade 3 or 4 as per NCI-CTCAE (version 4.0) (Grade 3= Severe, Grade 4= Life-threatening) were reported.
| Participants | Enzalutamide |
|---|---|
| Hematology: Leukocytes | 1 |
| Hematology: Lymphocytes | 9 |
| Hematology: Neutrophils | 1 |
| Chemistry: Alkaline Phosphatase | 1 |
| Chemistry: Bilirubin | 1 |
| Chemistry: Glucose | 4 |
| Chemistry: Phosphate | 1 |
Collected over Baseline up to 87 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Enzalutamide | 88/118 (74.6%) | 29/118 (24.6%) | 106/118 (89.8%) |
| Event | Enzalutamide |
|---|---|
| Disease progressionGeneral disorders | 3/118 |
| Malignant pleural effusionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 3/118 |
| Metastatic painNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 3/118 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 3/118 |
| Pericardial effusionCardiac disorders | 2/118 |
| ConstipationGastrointestinal disorders | 2/118 |
| Lung infectionInfections and infestations | 2/118 |
| SepsisInfections and infestations | 2/118 |
| Breast cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/118 |
| Spinal cord compressionNervous system disorders | 2/118 |
| Event | Enzalutamide |
|---|---|
| FatigueGeneral disorders | 49/118 |
| NauseaGastrointestinal disorders | 40/118 |
| Decreased appetiteMetabolism and nutrition disorders | 22/118 |
| DiarrhoeaGastrointestinal disorders | 18/118 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 18/118 |
| ConstipationGastrointestinal disorders | 17/118 |
| Back painMusculoskeletal and connective tissue disorders | 17/118 |
| HeadacheNervous system disorders | 17/118 |
| InsomniaPsychiatric disorders | 17/118 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 13/118 |
Intent-to-treat (ITT) population included all enrolled participants who had positive androgen receptor (AR+) breast cancer as assessed by central review and received at least 1 dose of study drug.
| Age, Continuous(years) | Enzalutamide |
|---|---|
| Mean | 58.3 ± 12.95 |
| Sex: Female, Male(Participants) | Enzalutamide |
|---|---|
| Female | 118 |
| Male | 0 |
| Ethnicity (NIH/OMB)(Participants) | Enzalutamide |
|---|---|
| Hispanic or Latino | 4 |
| Not Hispanic or Latino | 108 |
| Unknown or Not Reported | 6 |
| Race (NIH/OMB)(Participants) | Enzalutamide |
|---|---|
| American Indian or Alaska Native | 1 |
| Asian | 6 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 20 |
| White | 91 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
Showing the first 100 of 132 sites across 7 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Jun 2013 to primary completion in Mar 2015, 20 months.
Results were first posted in Aug 2018, 3 years 5 months after primary completion. A results delay was requested in Mar 2016.
Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 20 months is below that.
Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Enzalutamide